Preclinical In-vivo Imaging Market Size, Share, Industry, Forecast and Outlook (2023-2030)

Preclinical In-vivo Imaging Market is segmented By Modality (Optical Imaging Systems, Preclinical Nuclear Imaging Systems, Micro-MRI Systems, Micro-Ultrasound Systems, Micro-CT Systems, Preclinical Photoacoustic Imaging Systems, Preclinical Magnetic Particle Imaging (MPI) Systems), By Reagent (Preclinical Optical Imaging Reagents, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents, Preclinical CT contrast agents), By Application (Research and development, Drug discovery), By Distribution Channel (Pharmaceutical companies, Biotechnology companies, Research institutes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Report Overview

Preclinical In-vivo Imaging Market size was valued at USD 936.1 million in 2022 and is estimated to reach at a compound annual growth rate (CAGR) of 6.40% over the forecast period 2023 to 2030.

Preclinical in-vivo imaging is used in live animal research for drug development. Preclinical imaging is also used to monitor the treatment response for early indications of efficacy. The presence of technological development of in vivo imaging allows for studying the disease at the molecular level in a quantitative way. The major factors leading to the growth of the preclinical imaging market include technological advancements in molecular imaging, increasing demand for non-invasive small animal imaging techniques, and an increase in preclinical research funding, by both private and public organizations.

Numerous elements such as strong Research & Developments for life science research, speed acceptance of new molecular imaging technologies, altering regulatory situation, continue government support with funds and acceptance, the prominent occurrence of pharma and biotech organizations, and increasing consumer preference for multimodal systems, and boosting the growth of the global preclinical in vivo imaging market in the countries such as UAE, Egypt, Qatar, and South Africa.

Preclinical In-vivo Imaging Market Scope

For More Insights about the Market Request Free Sample

Key Insights in the Industry:

• Emerging factors leading to the global preclinical in-vivo imaging market growth contain the advancements in new technological molecular imaging, rising interest in non-invasive small animal imaging methods, and a surge in preclinical research funding from both public and private organizations.
• North America's preclinical in-vivo imaging market controls the largest share of the global market while the United States has the utmost share in the North American region.
• Rising R&D spending and the convenience of a well-established research structure are boosting the preclinical in-vivo imaging market growth enhancement in the United States.
• North America holds the largest share of the global preclinical imaging market, while the U.S. has the maximum share in North America.
• Europe's preclinical in-vivo imaging market is controlling the global market with the highest share over the period 2022-2029.
• Surged revenue and also increasing aged population in countries such as Germany, and United Kingdom are producing the largest share in the Europe market over the forecast period 2022-2029.
• Asia Pacific region is one of the speedy developing regions in the global market. However, Asia pacific preclinical in-vivo imaging market is projected to record a prominent market share throughout the forecast period 2022-2029.
• China market is expected to control the Asia Pacific market between 2022 and 2029, and the country is projected to record the major share. India is one of the fast-developing economies in the APAC region, and it is projected to show a significant growth rate in the global market in the next coming years.
• The Middle East and Africa preclinical in-vivo imaging market will continue its dominance in coming years, countries in MEA such as Saudi Arabia is expected to control the middle east and Africa region over the forecast period due to growing investment for R&D doubled with a greater number of research and clinical laboratories are boosting the growth of the market in Saudi Arabia.
• Saudi Arabia is predicted to dominate the MEA preclinical in-vivo imaging market during the forecast period due to the region having developed infrastructure, many preclinical projects, large public and private companies, and higher adoption rates of technically advanced devices in this region.
• In addition, increasing funding for research and development coupled with a large number of research institutes is accelerating the growth of the market in Saudi Arabia.

Market Dynamics

The global preclinical in-vivo imaging market is driven by technological advancements in imaging modalities, increasing demand for non-invasive small animal imaging techniques, a rise in preclinical research funding by both private and public organizations, and an increasing prevalence of chronic diseases.

The growing prevalence of chronic diseases such as cancer, cardiovascular, rheumatoid arthritis, neurological disorders, and other diseases are expected to boost the market throughout the forecast. For instance, the WHO has reported that cancer is the second leading cause of death globally and is responsible for 9.6 million deaths in 2018 and worldwide, about 1 in 6 deaths is only because of cancer. Also, around 70% of deaths from cancer occur in low and middle-income countries. WHO stated that around 17.9 million people die each year from cardiovascular diseases, and globally, it accounts for 31% of deaths.

The presence of technological developments in imaging is expected to drive the market. For instance, “Aspect’s M2,” a preclinical imaging product developed by Aspect imaging, is used for drug development. Also, newer technologies like photoacoustic tomography and confocal laser endomicroscopy lend the ability to identify critical and highly specific biomarker information for oncology, immunology, and neurology strategies. These approaches are expected to enhance preclinical and translational research significantly.

The presence of innovative product launches related to preclinical in-vivo imaging is expected to drive the market. For instance, in 2018, next-generation SPECT cameras with cadmium zinc telluride (CZT) detectors can reduce the patient radiation dose and shortens the examination time.

Increasing funding for preclinical research is also expected to boost the market. For instance, in 2017, the Alzheimer’s Drug Discovery Foundation (ADDF) accepted Letters of Intent which filled the translational funding gap between research and later-stage drug development by funding preclinical drug discovery. Also, it has provided funding up to USD 5 million for preclinical studies. In 2015 the Deutsches Zentrum fur Herz-Kreislaufforschung e.V. (DZHK) has provided Euro 6 million for the preclinical research projects.

However, with the high installation and operational costs of preclinical imaging modalities, stringent regulations are likely to hamper the market.

The high product cost decreases the adoption rates in academic institutions. Also, the stringent restrictions that are placed on animal testing due to the regulations enforced by organizations, which protect animal rights are impeding the market. For instance, in Europe, animal testing for cosmetics is banned. Therefore, the adoption of several alternative methods like micro-dosing, virtual testing of new drugs, and the development of computerized databases for testing purposes is increasing rapidly.

Market Segmentation Analysis

By Modality:

• Optical Imaging Systems
• Preclinical Nuclear Imaging Systems
• Micro-MRI Systems
• Micro-Ultrasound Systems
• Micro-CT Systems
• Preclinical Photoacoustic Imaging Systems
• Preclinical Magnetic Particle Imaging (MPI) Systems

Micro-ultrasound systems are expected to propel the market over the forecast period. This is owing to the recent launches and the added advantages. It is a miniature version of ultrasound that boosts the efficacy of the techniques and has a broader range of applications, mainly in research related to small animal models. Also, they decrease the number of animals required for a particular study. For instance, on May 3, 2018, Exact Imaging received FDA 510(k) Clearance for its FusionVu™ application on the ExactVu micro-ultrasound system.

Micro-CT systems are also expected to drive the market, owing to the recent launches and increased number of installations. For instance, on February 6, 2019, Bruker announced the new SKYSCAN 1273 benchtop 3D X-ray microscope based on micro-CT technology. On September 6, 2018, MILabs announced the installation of its next-generation Adaptive U-CTXUHR at Sydney Imaging, a core research facility of the University of Sydney.

By Reagent:

• Preclinical Optical Imaging Reagents
• Preclinical Nuclear Imaging Reagents
• Preclinical MRI Contrast Agents
• Preclinical Ultrasound Contrast Agents
• Preclinical CT contrast agents

Optical imaging systems are expected to grow at a high rate over the period forecast. The Trimodality (SPECT/PET/CT) Systems segment of it, is expected to boost the market. This is owing to the presence of an increased number of installations and acquisitions. For instance, on August 22, 2019, Kawasaki Medical University, Yokohama’s research hub for state-of-the-art medical science and services acquired an ultra-high-resolution E-Class U-SPECT6/CT system for preclinical imaging and installed the first MILabs E-Class U-SPECT6/CT in Japan.

By Application:

• Research and development
• Drug Discovery

By application, the research and development segment is expected to dominate the market. This is owing to the increased use of modalities for research and drug development. For instance, on September 7, 2016, Bruker unveiled two new preclinical imaging systems at the World Molecular Imaging Congress 2016.  They are designed to give the highest performance and improved convenience for routine imaging and enable novel translational research into the progression, causes, as well as a potential diagnosis, and treatment of the disease.

By Distribution channel:

• Pharmaceutical companies
• Biotechnology companies
• Research institutes
• Others

By distribution channel, pharmaceutical companies are expected to dominate the market, owing to the increased application of molecular imaging to clinical development, especially late-stage development. Pharmaceutical companies use the instruments and reagents for preclinical and clinical development directly in-house and indirectly through CROs and academic centers. Preclinical imaging is growing faster than clinical imaging, which is driven by pharmaceutical companies’ need for ever-earlier attrition of unpromising drugs.

Geographical Share

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa

North America is dominating the global market in 2018 and is estimated to hold a significant market size over the forecast period (2020-2027) owing to the rapid adoption of several types of modalities, robust research and development infrastructure for life science research, technological advancements, growing prevalence of chronic diseases such as cancer, cardiovascular disease, and others, and increasing funding for preclinical research activities. The preclinical imaging market in North America is primarily driven by factors like a high volume of preclinical research in this region, easy availability and accessibility of resources, and rising government funding for research and innovation in Canada.

North America holds the largest share of the global preclinical imaging market, while the U.S. has the maximum share in North America. The preclinical imaging industry in North America is primarily driven by factors like a high volume of preclinical research in this region, easy availability and accessibility of resources, and rising government funding for research and innovation in Canada. The preclinical imaging market in North America is majorly driven by aspects probably a high volume of preclinical research in the North American region, quick availability, and convenience of resources, and the increasing government spending for research and innovation in Canada.

The growing prevalence of chronic diseases is expected to boost the market over the forecast period. For instance, the National Cancer Institute has reported that about 1,685,210 new cases of cancer are diagnosed in the US, and 595,690 people died from the disease by 2016 end.  The Center for Disease Control and Prevention has reported that about 610,000 people die of heart disease in the US each year. Coronary heart disease (CHD) is the most common type of heart disease, killing over 370,000 people yearly.

The rising number of mergers, acquisitions, and product launches by the key players is expected to boost the market throughout the forecast. For instance, on February 22, 2017, FUJIFILM VisualSonics Inc., announced the launch of the new Vevo LAZR-X, the world’s only customizable imaging platform combining ultrahigh-frequency ultrasound and photoacoustics for animal research applications.

Competitive Landscape

The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the global market for the preclinical in-vivo imaging. some of the major players profiled in the market report are;

1. Bruker Corporation
2. Siemens A.G
3. TriFoil Imaging
4. PerkinElmer
5. VisualSonics Inc. (Fujifilm)
6. MILabs B.V.
7. Mediso Ltd
8. Agilent Technologies

Recent Developments in the Global Market:

• On June 8, 2018, MILabs launched the E-Class line of high-performance, economical PET, SPECT, and CT systems.
• On June 12, 2018, Bruker launched the SKYSCAN 2214, a multiscale X-ray nano-CT system with a unique X-ray source with outstanding precision.
• On June 5, 2017, MILabs B.V. launched a next-generation integrated PET-SPECT-OI-CT imaging solution, named the 5-series. It enables more significant breakthroughs in anatomical, functional, and molecular imaging.
• On April 5, 2016, AXT expanded its preclinical imaging portfolio with the addition of inviter's innovative software platforms.
• On March 25, 2019, Jagiellonian University in Kraków became the first institute in Poland to install MILabs’ Adaptive U-CT for in-vivo preclinical imaging.
• On October 2, 2018, the Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake City, UT, was the first site in the US to install the nanoScan PET/MRI 3T preclinical in the Vivo imaging system. This was the 10th installation of the nanoScan MRI 3T globally.
• On October 2, 2018, with the successful installation of the 100th Mediso multi-modality preclinical PET system, the Tulane National Primate Research Center (TNPRC), a division of Tulane University, became the fourth site in North America to install the MultiScan LFER150 PET/CT preclinical imager.